Rare disease drugmaker Alexion to move headquarters to Boston

Alexion Pharmaceuticals said Tuesday that it plans to move its headquarters from New Haven, Connecticut to Boston's Seaport District by mid-2018, becoming the latest big drugmaker to make Massachusetts home. Alexion (Nasdaq: ALXN) said that 400 positions would be located in the new headquarters at 121 Seaport Blvd., with around 450 employees remaining in New Haven. Alexion already has an 81,000 square-foot research and development office in Lexington. The 17-story, elliptical-shaped glass office…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news